Abstract Details

Title Serum Neurofilament Light Chain and Glial Fibrillary Acid Protein in Patients With Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-006

Objective To investigate serum Neurofilament light chain (S-NFL) and serum glial fibrillary acid protein (s-GFAP) in a MS patients cohort

Background Serum neurofilament light chain (s-NFL), a marker of neuronal injury is considered as a promising prognostic biomarker in multiple sclerosis (MS). S-NFL is correlated with acute inflammation and neurodegenerative process. Additional biomarkers are needed to distinguish patients at risk from relapse and patients at risk from progression

Design/Methods

We assessed serum NFL and GFAP (Neurology 4-plex A Simoa kit, Quanterix, USA) in 129 MS patients

CSF and serum values were analysed in 39 patients to evaluate serum/CSF correlation.

A statistical analaysis was done to compare MS characteristics and serum NFL and GFAP values.

Results

Mean age at blood sample was respectively 51, 41 and 35 years in PPMS, RRMS without relapse and RRMS with recent relapse and mean disease duration was 4, 8 and 1.3 years. Correlation between CSF and serum level were good for both NFL and GFAP (respectively r=0.63 and r=0.60, both p<0.001). Both s-NFL (9.3±5 vs 13.6±6.6 pg/ml) and s-GFAP (83±38 vs 130±73 pg/ml) were significantly lower in RRMS than in PPMS patients (respectively p=0.002 and 0.004). In RRMS patients, although it was not significant, s-GFAP (69 vs 87 pg/ml) was lower in patients with recent relapse. S-NFL were similar in the 2 groups (9.2 vs 9.4 pg/ml). There was no correlation between baseline s-NFL and s-GFAP and disability assessed by the EDSS.

Conclusions Our data confirm that s-NFL are higher in PPMS patients. Moreover, s-GFAP, a marker of astrogliosis is also significantly elevated in PPMS patients as compared to RRMS. Additionally, s-GFAP seem to be lower in patients with recent relapse. Even if its additional value is unknown, our data suggest that s-GFAP is another available serum biomarker that could be of interest in the evaluation of MS patients cohort

Authors/Disclosures
Xavier Ayrignac PRESENTER	Xavier Ayrignac has nothing to disclose.
	No disclosure on file
Clarisse Carra-Dalliere	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Pierre Labauge, MD	Dr. Labauge has nothing to disclose.

��ɫ��

��ɫ��